• Publications
  • Influence
Chimeric antigen receptor T cells for sustained remissions in leukemia.
TLDR
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. Expand
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
TLDR
The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL. Expand
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.
TLDR
Data demonstrating that CD28 costimulation enhances the in vitro survival of activated T cells and suggesting that an important role of CD28costimulation is to augment T cell survival during antigen activation is suggested. Expand
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
TLDR
A low dose of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. Expand
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
TLDR
It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL). Expand
A human memory T-cell subset with stem cell-like properties
TLDR
A long-lived human memory T cell population that has an enhanced capacity for self-renewal and a multipotent ability to derive central memory, effector memory and effector T cells is described. Expand
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia
TLDR
In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects. Expand
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1
TLDR
It is suggested that colocalization of PD-1 with CD3 and/or CD28 may be necessary for inhibition of T cell activation, and that recruitment of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2, and not the adaptor SRC homology 2 domain -containing molecule 1A, to the ITSM domain is needed. Expand
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
TLDR
O adoptive transfer of ex vivo expanded CCR5 ZFN–modified autologous CD4+ T cells in HIV patients is an attractive approach for the treatment of HIV-1 infection. Expand
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
TLDR
CCR5-modified autologous CD4 T-cell infusions are safe within the limits of this study, and HIV RNA became undetectable in one of four patients who could be evaluated. Expand
...
1
2
3
4
5
...